Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto®) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

NCT03887780 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03887780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03887780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto®) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
October 3, 2019
Completion date
December 16, 2024
Enrollment
504 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation (nvaf)